MESOBLAST LTD- SPON ADR (MESO)
US5907174016 - ADR
We assign a fundamental rating of 2 out of 10 to MESO. MESO was compared to 587 industry peers in the Biotechnology industry. MESO has a bad profitability rating. Also its financial health evaluation is rather negative. MESO is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
MESO had negative earnings in the past year.
In the past year MESO has reported a negative cash flow from operations.
In the past 5 years MESO always reported negative net income.
In the past 5 years MESO always reported negative operating cash flow.
1.2 Ratios
MESO has a better Return On Assets (-12.22%) than 88.55% of its industry peers.
The Return On Equity of MESO (-16.10%) is better than 89.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.22% | ||
| ROE | -16.1% | ||
| ROIC | N/A |
ROA(3y)-13.1%
ROA(5y)-12.74%
ROE(3y)-17.23%
ROE(5y)-16.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MESO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MESO does not have a ROIC to compare to the WACC, probably because it is not profitable.
MESO has more shares outstanding than it did 1 year ago.
MESO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MESO is higher compared to a year ago.
2.2 Solvency
MESO has an Altman-Z score of 1.38. This is a bad value and indicates that MESO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.38, MESO is in the better half of the industry, outperforming 67.18% of the companies in the same industry.
MESO has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
MESO has a Debt to Equity ratio of 0.22. This is in the lower half of the industry: MESO underperforms 67.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.38 |
ROIC/WACCN/A
WACC8.13%
2.3 Liquidity
MESO has a Current Ratio of 2.71. This indicates that MESO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MESO (2.71) is worse than 69.74% of its industry peers.
MESO has a Quick Ratio of 2.71. This indicates that MESO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.71, MESO is doing worse than 67.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.71 | ||
| Quick Ratio | 2.71 |
3. Growth
3.1 Past
MESO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.97%.
The Revenue for MESO has decreased by -26.56% in the past year. This is quite bad
MESO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -15.43% yearly.
EPS 1Y (TTM)-21.97%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q28.89%
Revenue 1Y (TTM)-26.56%
Revenue growth 3Y-38.44%
Revenue growth 5Y-15.43%
Revenue growth Q2Q-1.02%
3.2 Future
Based on estimates for the next years, MESO will show a very strong growth in Earnings Per Share. The EPS will grow by 94.71% on average per year.
The Revenue is expected to grow by 143.45% on average over the next years. This is a very strong growth
EPS Next Y-278.42%
EPS Next 2Y-102.88%
EPS Next 3Y94.71%
EPS Next 5YN/A
Revenue Next Year-23.16%
Revenue Next 2Y14.73%
Revenue Next 3Y141.74%
Revenue Next 5Y143.45%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MESO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MESO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MESO's earnings are expected to grow with 94.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-102.88%
EPS Next 3Y94.71%
5. Dividend
5.1 Amount
MESO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MESOBLAST LTD- SPON ADR
NASDAQ:MESO (5/10/2024, 7:05:50 PM)
After market: 7 -0.36 (-4.89%)7.36
+0.19 (+2.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap839.56M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.22% | ||
| ROE | -16.1% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.71 | ||
| Quick Ratio | 2.71 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-21.97%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-278.42%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-26.56%
Revenue growth 3Y-38.44%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y